Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials

Published:2019-01 Issue:1 Volume:20 Page:37-47
ISSN:1462-2416
Container-title:Pharmacogenomics
language:en
Short-container-title:Pharmacogenomics

Author:

Bousman Chad A¹²³,Arandjelovic Katarina⁴,Mancuso Serafino G⁵,Eyre Harris A⁴⁵⁶⁷,Dunlop Boadie W⁸

Affiliation:

1. Departments of Medical Genetics, Psychiatry, & Physiology & Pharmacology, University of Calgary, Calgary, Alberta T2N 4N1, Canada

2. Alberta Children's Hospital Research Institute, Calgary, Alberta T2N 1N4, Canada

3. Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta T2N 4N1, Canada

4. IMPACT SRC, School of Medicine, Deakin University, Geelong, Victoria, 3220, Australia

5. Department of Psychiatry, University of Melbourne, Melbourne, Victoria, 3220, Australia

6. Innovation Institute, Texas Medical Center, Houston, TX 77030, USA

7. CNSDose LLC, Westlake Village, CA 91359, USA

8. Department of Psychiatry & Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA

Abstract

Aim: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD). Patients & methods: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. Results & conclusion: A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI: 1.17–2.48; p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850). Pharmacogenetic-guided DSTs might improve symptom remission among those with MDD.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pgs-2018-0142

Reference51 articles.

1. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

2. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

3. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression

4. Using a pharmacogenomic algorithm to guide the treatment of depression

5. PREDICTIVE SOCIOECONOMIC AND CLINICAL PROFILES OF ANTIDEPRESSANT RESPONSE AND REMISSION

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study;Pharmaceuticals;2024-01-23

2. Effectiveness of pharmacogenomics on the response and remission of treatment-resistant depression: a meta-analysis of randomised controlled trials;General Psychiatry;2023-12

3. Association between genetic variants of GRM7 (rs1396409 and rs9883258) and treatment outcomes in Schizophrenic Egyptian patients;Nucleosides, Nucleotides & Nucleic Acids;2023-11-24

4. The role of pharmacogenetics in the treatment of major depressive disorder: a critical review;Frontiers in Psychiatry;2023-11-10

5. Multigenetic Pharmacogenomics–Guided Treatment vs Treatment As Usual Among Hospitalized Men With Schizophrenia;JAMA Network Open;2023-10-06